<DOC>
	<DOCNO>NCT03100149</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled , Phase 2 study evaluate efficacy intravenous RO7046015 versus placebo 52 week participant early Parkinson 's Disease ( PD ) untreated treated monoamine oxidase B ( MAO-B ) inhibitor since baseline . The study consist 2 part : 52-week , double-blind , placebo-controlled treatment period ( Part 1 ) eligible participant continue all-participants-on-treatment blind dose extension additional 52 week ( Part 2 ) .</brief_summary>
	<brief_title>A Study Evaluate Efficacy RO7046015 Participants With Early Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Idiopathic PD bradykinesia plus one cardinal sign PD ( rest tremor , rigidity ) present , without know suspected cause PD untreated treated MAOB inhibitor Body weight range : &gt; /=45 kg/ 99 pound ( lb ) less equal ( &lt; /= ) 110 kg/242 lb Body mass index ( BMI ) 18 34 kilogram per metersquared ( kg/m^2 ) A diagnosis PD 2 year less screen Hoehn Yahr Stage I II A screening brain DaTSPECT consistent PD ( central reading ) Clinical status require dopaminergic PD medication expect require dopaminergic treatment within 52 week baseline If presently treat PD , stable dose MAOB inhibitor ( rasagiline selegiline ) least 90 day prior baseline expect change within 52 week For woman childbearing potential : use highly effective contraceptive method ( result failure rate &lt; 1 percent [ % ] per year ) treatment period least 30 day ( longer require local regulation ) last dose study drug For men female partner childbearing potential pregnant female partner , must use condom treatment period least 30 day ( longer require local regulation ) last dose study drug avoid expose embryo . Men must refrain donating sperm period . The female partner use contraception method failure rate &lt; 1 % per year treatment period least 30 day ( longer require local regulation ) last dose study drug Clinical sign past medical history indicate Parkinson syndrome idiopathic PD , include limited , progressive supranuclear gaze palsy , multiple system atrophy , druginduced parkinsonism , essential tremor , primary dystonia Known carrier certain familial PD gene ( specify study protocol ) History PD relate freeze episode fall A diagnosis significant CNS disease Parkinson 's disease ; history repeat head injury ; history epilepsy seizure disorder febrile seizures child Mini Mental State Examination ( MMSE ) &lt; /=25 Reside nursing home assist care facility History screen brain magnetic resonance imaging ( MRI ) scan indicative clinically significant abnormality Concomitant disease condition could interfere , treatment might interfere , conduct study , would , opinion Investigator , pose unacceptable risk participant study interfere participant 's ability comply study procedure abide study restriction , ability interpret safety data Any significant cardiovascular condition Any significant laboratory abnormality Lactating woman Prior treatment dopaminergic medication ( example , levodopa dopaminergic agonist ) clinical treatment response clinical treatment response inconsistent PD Use follow : catecholOmethyl transferase ( COMT ) inhibitor ( entacapone , tolcapone ) , amantadine anticholinergic , dopaminergic medication ( levodopa ergot nonergot [ pramipexole , ropinirole , rotigotine ] dopamine agonist ) total 60 day within 60 day baseline Antiepileptic medication nonseizurerelated treatment remain stable least 60 day prior baseline Antidepressant anxiolytic use remain stable least 90 day prior baseline Use follow within 90 day prior baseline : neuroleptic , metoclopramide , alpha methyldopa , clozapine , olanzapine , flunarizine , amoxapine , amphetamine derivative , reserpine , bupropion , buspirone , cocaine , mazindol , methamphetamine , methylphenidate , norephedrine , phentermine , phenylpropanolamine , modafinil Participated investigational drug device study include prior treatment PD involve intracranial surgery implantation device Any prior treatment investigational PDrelated vaccine Prior participation RO7046015 PRX002 study Receipt investigational product device , participation drug research study within period 30 day ( 5 halflives drug , whichever long ) baseline Receipt monoclonal antibody investigational immunomodulator within 180 day ( 5 halflives , whichever long ) baseline Systemic corticosteroid immunomodulating drug within 30 day prior baseline Allergy component RO7046015 know hypersensitivity Infusionrelated reaction ( IRR ) administration monoclonal antibody Any contraindication obtain brain MRI For participant consent provide optional cerebrospinal fluid ( CSF ) sample lumbar puncture ( LP ) : LP perform participant contraindication undergo LP Donation blood 500 milliliter ( mL ) within three month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>